Stacks
Interaction Unknown
Yuan et al. (MDPI, 2026) characterise BPC-157 as operating across two separable axes — a regenerative axis anchored in VEGFR2–Akt–eNOS signalling and FAK/paxillin fibroblast activation, and an analgesic axis running through nitric oxide modulation and dopaminergic–opioid interaction. For stack designers, each axis creates a distinct interaction node: compounds converging on the same pathway require co-administration scrutiny.
July 21, 2026
·
9 min read
Stacks
Interaction Unknown
The 2026 Pharmaceuticals critical analysis (DOI: 10.3390/ph19020297) establishes that semaglutide produces tissue-specific GLP-1R outputs: cardioprotective in myocardium, proliferative in thyroid C-cells under rodent conditions. For cardio-oncology stack design, this dual signal means the compound can be a rational co-administration partner with anthracycline-class agents while requiring hard exclusion in thyroid-risk populations — two decisions made in parallel, not sequentially.
July 21, 2026
·
9 min read
Stacks
Interaction Unknown
No controlled human trial has tested BPC-157 plus TB-500 co-administration for torn ligament recovery as of 2026. The combination rationale is mechanistically coherent — the two compounds operate through non-overlapping repair pathways — but the additive-effect claim rests entirely on preclinical single-compound data and uncontrolled self-experimentation reports. No combined benefit has been formally quantified in any ligament model.
July 16, 2026
·
9 min read
Stacks
Interaction Unknown
GLP-1 receptor agonists and AOD-9604 operate through non-overlapping receptor systems — GLP-1R–mediated central appetite suppression versus β3-adrenergic–driven peripheral lipolysis — making direct receptor competition structurally impossible. No co-administration RCT exists as of 2026. Sequencing logic is built from each compound's independent pharmacokinetics: AOD-9604's ~4-minute serum half-life versus semaglutide's ~168-hour half-life defines the only meaningful timing variable.
July 15, 2026
·
9 min read
Stacks
Interaction Unknown
Retatrutide adds glucagon receptor (GCGR) agonism to the GLP-1R/GIPR dual-agonist framework, driving hepatic fatty acid oxidation and thermogenic energy expenditure. Phase 3 TRIUMPH-1 data show approximately 28% mean weight loss at 80 weeks, exceeding dual-agonist benchmarks. Protocol designers must account for a longer titration schedule and a hepatic-fat reduction vector absent in dual-agonist stacks.
July 15, 2026
·
9 min read
Stacks
Interaction Unknown
Incretin mimetics — GLP-1R and GIPR agonists — acutely suppress AgRP neuron firing in the arcuate nucleus, short-circuiting the orexigenic signal that normally amplifies hunger when circulating leptin falls during caloric restriction. This neural override partially decouples fasting adherence from the leptin-depletion cascade, though it does not prevent the absolute leptin decline accompanying fat-mass loss.
July 14, 2026
·
9 min read